TET2 and acute myeloid leukemia: For example, from our cohort of 490 patients with indications of AML, TET2 had the highest mutation rate (17% of patients) followed by ASXL1, TP53, FLT3, NPM1, SRSF2, DNMT3A, IDH2, RUNX1 and NRAS (10~15%), frequencies similar to literature [37].